

Deep Learning for Biomedicine

Genomics and Drug Design



Truyen Tran
Deakin University



truyen.tran@deakin.edu.au



truyentran.github.io



[@truyenoz](https://twitter.com/truyenoz)




letdataspeak.blogspot.com



goo.gl/3jJ100



Hanoi, Jan 2019



Agenda

Deep learning

- Neural architectures
- Generative models

Genomics

- Nanopore sequencing
- Genomics modelling

Drug design

- Bioactivity prediction
- Drug generation

Future outlook



High-impact & data-intensive.

- Andrew Ng's rule: impact on 100M+ people.
- Biomedicine is the only industry that will never shrink!


Ripe for innovations fuelled by deep learning techniques.

- Major recent advances and low hanging fruits are being picked.


Great challenges:

- High volume and high dimensional;
- Great privacy concerns;
- Need integrated approach to encompass great diversities.


It is the right time to join force with biomedical scientists!




healthpages.org



ase.edu



pharmacy.umaryland.edu



openi.nlm.nih.gov



marketingland.com



Big Rooms in Biomedicine

Machine learning = feature engineering = \$\$\$

\$3M Prize, 3 years

170K patients, 4 years worth of data

Predict length-of-stay next year

Not deep learning yet (early 2013), but strong ensemble needed → suggesting dropout/batch-norm



Dashboard

Leaderboard - Heritage Health Prize

This competition has completed. This leaderboard reflects the final standings.

#	Δ1w	Team Name	*in the money	Score	Entries	Last Submission UTC (Best - Last Submission)
1	-	POWERDOT	★	0.461197	671	Thu, 04 Apr 2013 05:12:00 (-12.3d)
2	↑60	EXL Analytics		0.462247	555	Thu, 04 Apr 2013 00:06:09 (-3.4d)
3	↑15	J.A. Guerrero		0.462417	173	Thu, 04 Apr 2013 06:03:09
47	↓4	Midnight Run		0.467358	60	Fri, 15 Feb 2013 02:18:14 (-194.5d)
48	↓4	PookyPANTS		0.467387	6	Fri, 03 Feb 2012 21:30:44
49	↑31	Vietlabs		0.467543	8	Thu, 28 Mar 2013 22:36:51
50	↓5	jsf		0.467545	18	Wed, 03 Apr 2013 17:31:42 (-118d)

This is me!

O'REILLY





Feature Engineering for Machine Learning

PRINCIPLES AND TECHNIQUES FOR DATA SCIENTISTS


Alice Zheng & Amanda Casari

Building block: Feature extractor


Integrate-and-fire neuron




Feature detector



Block representation




Building block: Recurrence




Source: <http://karpathy.github.io/assets/rnn/diags.jpeg>

Building block: Convolution



adeshpande3.github.io

Building block: Message passing



#REF: Pham, Trang, et al. "Column Networks for Collective Classification." AAAI. 2017.

Supervised deep learning: steps

Step 0: Collect LOTS of high-quality data

- Corollary: Spend LOTS of time, \$\$ and compute power

Step 1: Specify the **computational graph** $Y = F(X; W)$

Step 2: Specify the loss $L(W; D)$ for data $D = \{(X1,Y1), (X2,Y2), \dots\}$

Step 3: Differentiate the loss w.r.t. W (now mostly automated)

Step 4: Optimize the loss (a lot of tools available)

Generative models

Many applications:



- Text to speech
- **Simulate data that are hard to obtain/share in real life (e.g., healthcare)**
- Generate meaningful sentences conditioned on some input (foreign language, image, video)
- Semi-supervised learning
- Planning

$$\mathbf{v} \sim P_{model}(\mathbf{v})$$
$$P_{model}(\mathbf{v}) \approx P_{data}(\mathbf{v})$$

Variational Autoencoder


(Kingma & Welling, 2014)

Two separate processes: generative (hidden \rightarrow visible) versus recognition (visible \rightarrow hidden)



Generative adversarial networks

(Adapted from Goodfellow's, NIPS 2014)



Progressive GAN: Generated images



female1.png



female2.png



female3.png



female4.png



female6.png



male1.png



male2.png



male3.png

Karras, T., Aila, T., Laine, S., & Lehtinen, J. (2017). Progressive growing of GANs for improved quality, stability, and variation. *arXiv preprint arXiv:1710.10196*.

Deep learning

- Neural architectures
- Generative models



Genomics

- Nanopore sequencing
- Genomics modelling


Drug design

- Bioactivity prediction
- Drug generation

Future outlook



MtDNA ring



<https://qph.ec.quoracdn.net/main-qimg-2c39fede406d71fb534bbae6cc9b8aad-c>
https://en.wikipedia.org/wiki/Mitochondrial_DNA

Human genome

3 billion base-pairs (characters), 20K genes, 98% non-coding regions


Any two random persons share 99.9% genome

The 0.1% difference is thought to account for all variations between us

- Appearance: Height (80% heritable), BMI, hair, skin colors
- IQ, education levels
- Genetic disorders such as cancers, bipolar, schizophrenia, autism, diabetes, etc.

Any two random persons share about 60% variations (SNV/SNP)

As we age, there are small mutations within our cells



<https://neuroendoimmune.files.wordpress.com>

Sequencing

The first step is to read (sequence) the DNA/MtDNA, and represent the information as string of characters (A,C,G,T) in computer.


The most popular technique these days read short sequences (hundreds of characters), and align.

Each position is read typically at least 30 times to get enough confidence → Huge storage!!!

String alignment is then the key to final sequence → Need super-computer to do this fast.

A DNA sequence is compared against the reference genome. Only the difference (0.1%) need to be stored.

- This does not usually apply for MtDNA, as each cell has as many as 500 MtDNAs, they are slightly different! More different as we age.



Source: <https://www.genome.gov>



Biologist
Bioinformatician



Physician
Health informatician



AI/ML/DL

How does deep learning work for biomedicine?



Discovery



Diagnosis




Prognosis



Efficiency

Nanopore sequencing (electrical signals → A|C|G|T)



Source: technologyreview.com



Source: ibtimes.co.uk

Continuous segmentation & labelling

Deep architectures for nanopore sequencing

Aimed at real time recognition

The setting is similar to speech recognition!

- → The early days used HMMs. Now LSTMs.


We will briefly review the latest:

- **Chiron** (Teng et al., May 2018, UQ, Australia)

Other GRU/LSTM variants

- Nanonet (Oxford Nanopore Technologies, 2016)
- BasecRAWller (Stoiber & Brown, May 2017)
- **DeepNano** (Boza et al., June 2017, Comenius University in Bratislava, Slovakia)

Chiron



Dataset	Basecaller	Identity Rate
Lambda	Metricor	0.8650 (-0.0246)
	Albacore	0.8896
	BasecRAWler	0.8154 (-0.0742)
	Chiron	0.8776 (-0.012)
<i>E. coli</i>	Metricor	0.8864 (-0.0193)
	Albacore	0.901 (-0.0047)
	BasecRAWler	0.8254 (-0.0803)
	Chiron	0.9057
<i>M. tuberculosis</i>	Metricor	0.8802 (-0.0117)
	Albacore	0.8919
	BasecRAWler	0.8241 (-0.0678)
	Chiron	0.8851 (-0.0068)
Human	Metricor	0.794 (-0.0446)
	Albacore	0.8386
	BasecRAWler	0.8149 (-0.0237)
	Chiron	0.8154 (-0.0232)

#REF: Teng, Haotien, et al. "Chiron: Translating nanopore raw signal directly into nucleotide sequence using deep learning", GigaScience, Volume 7, Issue 5, 1 May 2018, giy037.


Other recent works

Li, Yu, et al. "DeepSimulator: a deep simulator for Nanopore sequencing." *Bioinformatics* 1 (2018): 10.

Wick, Ryan R., Louise M. Judd, and Kathryn E. Holt. "Deepbiner: Demultiplexing barcoded Oxford Nanopore reads with deep convolutional neural networks." *PLoS computational biology* 14.11 (2018): e1006583.

Wang, Sheng, et al. "WaveNano: a signal-level nanopore base-caller via simultaneous prediction of nucleotide labels and move labels through bi-directional WaveNets." *Quantitative Biology* 6.4 (2018): 359-368.

Opportunities for Deep Learning in Genomics



Genetic diagnostics
Refining drug targets
Pharmaceutical development
Personalized medicine
Better health insurance
Synthetic biology

Some AI problems

DNA is a book, easy to read (costs less than \$1K to sequence), extreme difficult to comprehend.

- It has 3B characters (A,C,T,G), 46 volumes (chromosomes), 20K chapters.
- The longest book has less than 10M characters, 13 volumes ("A la recherche du temps perdu" (In Search of Lost Time), by Marcel Proust, 2012) – as recognized by Guinness World Records.

Short sequences (100 chars) are predictive of protein binding, also gene start/end.

Proteins are big 3D graphs interacting with the 1D-2D strings (DNA, RNA), and other proteins & drugs (which are graphs themselves).

Long chains of influence, from SNP to cell, tissue and organ functions.

Viruses can be generated/edited on computer, hence discrete sequence generation problem.

Filling the genotypes → phenotypes gap


Ultimate goals:

- Estimating explained variance in inheritability
- Discover risk factors
- Predicting individual phenotypes: Height, Glucose, BMI, IQ, Edu, Mental, Cancers...

Some paths under investigation

- Predicting the bio of the cells, DNA + MtDNA, and more
- Statistical modeling of genetic architectures, e.g., Bayesian, mixed linear models, Gaussian Processes.
- Motif modeling with DNA/RNA/protein, e.g., predict binding sites
- Developing data-efficient techniques for genomics
- Integrating multimodalities

GWAS: Genome-Wide Association Study



Setting:

- For each DNA, only differences from a reference genome are recorded.
- The differences are SNPs, one per dimension.

Problems

- Very high dimensional (typically **hundreds of thousands**), low sample size (typically **hundreds**)
- Missing/unreliable data
- Typically very weak association
- Combating the False Discovery Rate (FDR) due to multiple parallel hypotheses: Individual p -value must be extremely small, e.g. **5×10^{-8}**

Diet networks for GWAS

#REF: Romero, Adriana, et al. "Diet Networks: Thin Parameters for Fat Genomic." *arXiv preprint arXiv:1611.09340* (2016).



Use a “hypernet” to generate the main net.

Features are embedded (not data instance).

Unsupervised autoencoder as regularizer.

Works well on country prediction on the 1000 Genomes Project dataset.

- But this is a relatively easy problem. PCA, even random subspace can do quite well!



Images taken from the paper

GWAS: Challenges

We are detecting rare events!!!

Results hard to replicate across studies.

- Model stability?

SNP → phenotypes seem impossible.

If it is (e.g., race prediction), little insights can be drawn upon.

The pathway is deep and complex

- Room for deep learning?


Room for structured models

- SNP annotations
- Spatial relationships
- Evolutionary trees

THE GENOME-WIDE TIDE

Large genome-wide association studies that involve more than 10,000 people are growing in number every year — and their sample sizes are increasing.

Sample sizes: ■ More than 200,000 ■ 100,000–199,999 ■ 50,000–99,999 ■ 10,000–49,999



NATURE | NEWS

New concerns raised over value of genome-wide disease studies

Large analyses dredge up 'peripheral' genetic associations that offer little biological insight, researchers say.

Ewen Callaway

15 June 2017

PDF

Rights & Permissions



Quinn16.pdf

CB-Insights_Health....pdf

Show all

Rooms for deep learning

Bridge the genotype-phenotype gap

- Incorporating HUGE amount of data
- Modelling the multiple layers of complex biological processes in between.
- Starting from the DNA and its immediate functions, e.g., **protein binding, gene start, alternative splicing, SNP annotations**.

Deep learning has shown to work well in cognitive domains, where human can perform in less than a second.


- We need to be super-human to bridge the gap.

New models for 2% of coding part, as well as 98% non-coding (probably having regulatory functions)

Incorporating biological understanding into model, not the black-box.


Use of feedforward nets: Tissue-regulated splicing code

#REF: Leung, Michael KK, et al.
"Deep learning of the tissue-regulated splicing code." *Bioinformatics* 30.12 (2014): i121-i129.




Use of CNNs: Discovery of DNA motifs

DeepBind (Alipanahi et al, Nature Biotech 2015)





The restriction enzyme EcoRV (green)

Source: wikipedia.org/wiki/DNA-binding_protein




Use of CNNs: FIDDLE

#REF: Eser, Umut, and L. Stirling Churchman. "FIDDLE: An integrative deep learning framework for functional genomic data inference." *bioRxiv* (2016): 081380.




THE CHROMPUTER

Integrating multiple inputs (1D, 2D signals, sequence)
to simulatenously **predict multiple outputs**




Chromatins



User of CNN+RNNs: DanQ

#REF: Quang, Daniel, and Xiaohui Xie.
"DanQ: a hybrid convolutional and recurrent deep neural network for quantifying the function of DNA sequences." *Nucleic acids research* 44.11 (2016): e107-e107.



More models/frameworks

DragoNN


DeepChrome

DeepSEA

Basset

DeepBound

...



<http://kundajelab.github.io/dragonn>

What make biomedicine hard for deep learning?

Great diversity but may be small in size

High uncertainty, low-quality/missing data

Reusable models do not usually exist

Human doesn't know how to read biomedicine (Brendan Frey, U of Toronto)

Require deep thinking for a reasonable deep architecture

However, at the end of the day, we need only a few generic things:

- Vector → DNN (e.g., highway net) | Sequence → RNN (e.g., LSTM, GRU)
- Repeated motifs → CNN | Set → Attention
- Graphs → Conv graphs; Column Networks
- Generative models → VAE; GAN

Agenda

Deep learning

- Neural architectures
- Generative models

Genomics


- Nanopore sequencing
- Genomics modelling

Drug design

- Bioactivity prediction
- Drug generation

Future outlook

Leading Companies Advanced AI in Healthcare and Drug Discovery




Drug Discovery	Pharma Corporations	Tech Corporations	Advanced R&D in Healthcare
INSILICO MEDICINE, Exscientia, Cloud Pharmaceuticals	gsk	Tencent 腾讯	XtalPi, Atomwise
CYCLICA, Atomwise, Numerate	MERCK	Alibaba.com	XtalPi
XtalPi, Biovista, IBM Watson	Pfizer	amazon	XtalPi
Exscientia, BERG, RECURSION	SANOFI	Baidu 百度	Atomwise
AiCure, Numerate, NuMedii	Boehringer Ingelheim	Google	XtalPi
Biovista, INSILICO MEDICINE	NOVARTIS	IBM	IBM Watson
Atomwise, CYCLICA	Roche	NVIDIA	INSILICO MEDICINE
AiCure, GNS HEALTHCARE	Johnson & Johnson	Canon	
BenevolentAI		Apple	
INSILICO MEDICINE	WuXi AppTec	HUAWEI	
BERG	AstraZeneca	intel	

Deep learning for drug discovery

Predicting bioactivities from molecules

Drug representation,
unsupervised learning from graphs

Generate from bioactivities to
molecular graphs



#REF: Roses, Allen D. "Pharmacogenetics in drug discovery and development: a translational perspective." *Nature reviews Drug discovery* 7.10 (2008): 807-817.

Traditional method: Combinatorial chemistry

Generate variations on a template

Returns a list of molecules from this template that

- Bind to the pocket with good pharmacodynamics?
- Have good pharmacokinetics?
- Are synthetically accessible?

#REF: Talk by Chloé-Agathe Azencott titled “Machine learning for therapeutic research”, 12/10/2017

First step: Map molecule → drug properties (binding/acting)


Drugs are small bio-molecules

Traditional techniques:

- Graph kernels (ML)
- Molecular fingerprints (Chemistry)

Modern techniques

- Molecule as graph: atoms as nodes, chemical bonds as edges



#REF: Penmatsa, Aravind, Kevin H. Wang, and Eric Gouaux. "X-ray structure of dopamine transporter elucidates antidepressant mechanism." *Nature* 503.7474 (2013): 85-90.


3 methods for bioactivity prediction

Graph memory networks (GMN) for drug bioactivity prediction



Graph attentional multi-label learning (GAML) for drug multi-target binding & repurposing

Relational dynamic memory networks (RDMMNs) for drug-drug / drug-protein interaction

Graph memory networks



Message passing as refining atom representation



#Ref: Pham, Trang, Truyen Tran, and Svetha Venkatesh. "Graph Memory Networks for Molecular Activity Prediction." *ICPR'18*.

Graph memory networks: Results






Figure 2: F1-score (%) for NCI datasets. FP = Fingerprint; RF = Random Forests; GBM = Gradient Boosting Machine. Best view in color.


Multi-target binding for drug repurposing



(a) A input graph with 4 nodes and 3 labels



(b) Input node update



(c) Label node update


#REF: Do, Kien, et al. "Attentional Multilabel Learning over Graphs-A message passing approach." *Machine Learning*, 2019.

Dataset	Metrics	Fingerprint		SMILES	Molecular Graph		
		SVM	HWN	GRU	WL+SVM	CLN	GAML
<i>9cancers</i>	m-AUC	81.94	85.95	83.29	86.06	88.35	88.78
	M-AUC	81.37	85.85	82.74	85.74	88.23	88.50
	m-F1	50.63	57.44	55.97	54.55	59.48	62.03*
	M-F1	50.71	57.29	55.99	54.54	59.50	62.14*
<i>50proteins</i>	m-AUC	79.85	77.46	79.11	81.62	82.08	82.82
	M-AUC	74.77	73.78	75.25	77.60	78.36	79.35*
	m-F1	17.21	16.37	16.08	17.04	18.37	20.47*
	M-F1	18.40	15.87	14.96	18.66	17.72	19.83*

Table 4: The performance in the multi-label classification with graph-structured input (m-X: micro average of X; M-X: macro average). SVM and HWN work on fingerprint representation; GRU works on string representation of molecule known as SMILES; WL+BR and CLN work directly on graph representation. Bold indicates better values. (*) $p < 0.05$.

#REF: Do, Kien, et al. "Attentional Multilabel Learning over Graphs-A message passing approach." *arXiv preprint arXiv:1804.00293*(2018).

Drug-drug interaction via *Relational Dynamic Memory Networks*



#REF: Pham, Trang, Truyen Tran, and Svetha Venkatesh. "Relational dynamic memory networks." *arXiv preprint arXiv:1808.04247*(2018).

Results on STITCH database

	CCI900		CCI800	
	AUC	F1-score	AUC	F1-score
Random Forests	94.3	86.4	98.2	94.1
Highway Networks	94.7	88.4	98.5	94.7
DeepCCI [31]	96.5	92.2	99.1	97.3
RDMN	96.6	92.6	99.1	97.4
RDMN+multiAtt	97.3	93.4	99.1	97.8
RDMN+FP	97.8	93.3	99.4	98.0
RDMN+multiAtt+FP	98.0	94.1	99.5	98.1
RDMN+SMILES	98.1	94.3	99.7	97.8
RDMN+multiAtt+SMILES	98.1	94.6	99.8	98.3

Table 3 The performance on the CCI datasets reported in AUC and F1-score. *FP* stands for fingerprint and *multiAtt* stands for multiple attentions.

Drug generation

We now have methods for compute bioactivities of a drug molecule

We need a reverse method to generate drug molecules from desirable bioactivities


The space of drugs is estimated to be $1e+23$ to $1e+60$

- **Only $1e+8$ substances synthesized thus far.**

It is impossible to model this space fully.

The current technologies are not mature for graph generations.

But approximate techniques do exist.



Source: pharmafactz.com

Old and new methods

Existing methods:

- Exhausted search through a fixed library
- Discrete local search: genetic algorithms, similar discrete interpolation
- The search space is still large.

Deep learning methods:

- Faster, more efficient to find new drugs
- Able of generate molecules that are likely the good candidates



Deep learning methods

Representing molecules using fingerprints

Representing graph as string, and use sequence VAEs or GANs.

Graph VAE & GAN

- Model nodes & interactions
- Model cliques

Sequences

- Iterative methods


Reinforcement learning

- Discrete objectives

Any combination of these + memory.

Kadurin, Artur, et al. "The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology." *Oncotarget* 8.7 (2017): 10883.

Molecule →
fingerprints



Input of the encoder : the fingerprint of a molecule

The decoder outputs the predicted fingerprint .

The generative model generates a vector E , which is then discriminated from the latent vector of the real molecule by the discriminator.

Molecule → string





Using SMILES representation of drug, to convert a molecular graph into a string

- SMILES = Simplified Molecular-Input Line-Entry System


Then using sequence-to-sequence + VAE/GAN to model the continuous space that encodes/decodes SMILES strings

- Allow easy optimization on the continuous space

#REF: Gómez-Bombarelli, Rafael, et al. "Automatic chemical design using a data-driven continuous representation of molecules." *arXiv preprint arXiv:1610.02415* (2016).




VAE for drug space modelling



Uses VAE for sequence-to-sequence.

#REF: Bowman, Samuel R., et al. "Generating sentences from a continuous space." *arXiv preprint arXiv:1511.06349* (2015).

Gómez-Bombarelli, Rafael, et al. "Automatic chemical design using a data-driven continuous representation of molecules." *ACS Central Science* (2016).



Drawbacks of string representation

String → graphs is not unique!





Lots of string are invalid

Precise 3D information is lost

Short range in graph may become long range in string

A better way is to encode/decode graph directly.

#REF: Gómez-Bombarelli, Rafael, et al. "Automatic chemical design using a data-driven continuous representation of molecules." *arXiv preprint arXiv:1610.02415* (2016).



N1CCN(CC1)C(C(F)=C2)=CC(=C2C4=O)N(C3CC3)C=C4C(=O)O

Better approach: Generating molecular graphs directly

No regular, fixed-size structures

Graphs are ***permutation invariant***:

- #permutations are exponential function of #nodes
- The probability of a generated graph G need to be marginalized over all possible permutations

Multiple objectives:

- **Diversity** of generated graphs
- **Smoothness** of latent space
- Agreement with or optimization of multiple “**drug-like**” objectives

GraphVAE

Handles irregular structures

- Predict the whole adjacency matrix, node types and edge types

Deals with variable size graph


- Bounded by the size of the largest graph in training data.

Handles permutation invariance

- Matching every pair of nodes in 2 graphs

Partially promotes diversity

#REF: Simonovsky, M., & Komodakis, N. (2018). GraphVAE: Towards Generation of Small Graphs Using Variational Autoencoders. *arXiv preprint arXiv:1802.03480*.



#REF: Simonovsky, M., & Komodakis, N. (2018). GraphVAE: Towards Generation of Small Graphs Using Variational Autoencoders. *arXiv preprint arXiv:1802.03480*.


Junction tree VAE

Junction tree is a way to build a “thick-tree” out of a graph

Cluster vocab:

- rings
- bonds
- atoms

Jin, W., Barzilay, R., & Jaakkola, T. (2018). Junction Tree Variational Autoencoder for Molecular Graph Generation. *ICML'18*.



Algorithm 2 Tree decomposition of molecule $G = (V, E)$

$V_1 \leftarrow$ the set of bonds $(u, v) \in E$ that do not belong to any rings.

$V_2 \leftarrow$ the set of simple rings of G .

for r_1, r_2 **in** V_2 **do**

 Merge rings r_1, r_2 into one ring if they share more than two atoms (bridged rings).

end for

$V_0 \leftarrow$ atoms being the intersection of three or more clusters in $V_1 \cup V_2$.

$\mathcal{V} \leftarrow V_0 \cup V_1 \cup V_2$

$\mathcal{E} \leftarrow \{(i, j, c) \in \mathcal{V} \times \mathcal{V} \times \mathbb{R} \mid |i \cap j| > 0\}$. Set $c = \infty$ if $i \in V_0$ or $j \in V_0$, and $c = 1$ otherwise.

Return The maximum spanning tree over cluster graph $(\mathcal{V}, \mathcal{E})$.

Jin, W., Barzilay, R., & Jaakkola, T.
(2018). Junction Tree Variational
Autoencoder for Molecular Graph
Generation. *ICML'18*.


Method	Reconstruction	Validity
CVAE	44.6%	0.7%
GVAE	53.7%	7.2%
SD-VAE ²	76.2%	43.5%
GraphVAE	-	13.5%
JT-VAE	76.7%	100.0%

Graphs + Reinforcement learning


Generative graphs are very hard to get it right: The space is too large!

Reinforcement learning offers step-wise construction: one piece at a time

- A.k.a. Markov decision processes
- As before: Graphs offer properties estimation



Play ground: MOSES



<https://medium.com/neuromation-io-blog/moses-a-40-week-journey-to-the-promised-land-of-molecular-generation-78b29453f75c>

The outlook

Read an extremely long book of DNA and answer any queries about it

- Memory-augmented neural networks (MANN), and
- Multiple hierarchical attentions and grammars

Instead of read, write (DNA/viruses/RNA/proteins)


Super-rich genome SNP annotation

The society of things (DNA/RNA/protein)

Transfer learning between cell types, tissues and diseases

Biology-driven deep nets (e.g., knowledge as memory)

Handling rare events (e.g., the role of memory)



(LeCun, 2015)

References

- Ching, Travers, et al. "Opportunities And Obstacles For Deep Learning In Biology And Medicine." *bioRxiv* (2018): 142760
- Eser, Umut, and L. Stirling Churchman. "FIDDLE: An integrative deep learning framework for functional genomic data inference." *bioRxiv* (2016): 081380.
- Leung, Michael KK, et al. "Deep learning of the tissue-regulated splicing code." *Bioinformatics* 30.12 (2014): i121-i129.
- Lanchantin, Jack, Ritambhara Singh, and Yanjun Qi. "Memory Matching Networks for Genomic Sequence Classification." *arXiv preprint arXiv:1702.06760* (2017).
- Pham, Trang, et al. "Column Networks for Collective Classification." *AAAI*. 2017
- Quang, Daniel, and Xiaohui Xie. "DanQ: a hybrid convolutional and recurrent deep neural network for quantifying the function of DNA sequences." *Nucleic acids research* 44.11 (2016): e107-e107.
- Teng , Haotien, et al. "Chiron: Translating nanopore raw signal directly into nucleotide sequence using deep learning", *GigaScience*, Volume 7, Issue 5, 1 May 2018, giy037.
- Wagstaff, K. L. (2012, June). Machine learning that matters. In *Proceedings of the 29th International Conference on Machine Learning* (pp. 1851-1856). Omnipress.
- Altae-Tran, Han, et al. "Low Data Drug Discovery with One-Shot Learning." *ACS central science* 3.4 (2017): 283-293.
- Angermueller, Christof, et al. "Deep learning for computational biology." *Molecular systems biology* 12.7 (2016): 878.
- Duvenaud, David K., et al. "Convolutional networks on graphs for learning molecular fingerprints." *Advances in neural information processing systems*. 2015.

References (cont.)

- Gómez-Bombarelli, Rafael, et al. "Automatic chemical design using a data-driven continuous representation of molecules." *arXiv preprint arXiv:1610.02415* (2016).
- Gupta, Anvita, et al. "Generative Recurrent Networks for De Novo Drug Design." *Molecular Informatics* (2017).
- Jin, W., Barzilay, R., & Jaakkola, T. (2018). Junction Tree Variational Autoencoder for Molecular Graph Generation. *arXiv preprint arXiv:1802.04364*.
- Kadurin, A., Aliper, A., Kazennov, A., Mamoshina, P., Vanhaelen, Q., Khrabrov, K., & Zhavoronkov, A. (2017). The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology. *Oncotarget*, 8(7), 10883.
- Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017). druGAN: an advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. *Molecular pharmaceuticals*, 14(9), 3098-3104.
- Kien Do, et al. "Attentional Multilabel Learning over Graphs-A message passing approach." *arXiv preprint arXiv:1804.00293*(2018).
- Kien Do, Truyen Tran, Svetha Venkatesh, "Learning Deep Matrix Representations"*arXiv preprint arXiv:1703.01454*
- Kusner, Matt J., Brooks Paige, and José Miguel Hernández-Lobato. "Grammar Variational Autoencoder." *arXiv preprint arXiv:1703.01925* (2017).
- Penmatsa, Aravind, Kevin H. Wang, and Eric Gouaux. "X-ray structure of dopamine transporter elucidates antidepressant mechanism." *Nature* 503.7474 (2013): 85-90.
- Pham, Trang, Truyen Tran, and Svetha Venkatesh. "Graph Memory Networks for Molecular Activity Prediction." *ICPR'18*.
- Roses, Allen D. "Pharmacogenetics in drug discovery and development: a translational perspective." *Nature reviews Drug discovery* 7.10 (2008): 807-817.
- Segler, Marwin HS, et al. "Generating focused molecule libraries for drug discovery with recurrent neural networks." *arXiv preprint arXiv:1701.01329* (2017).
- Simonovsky, M., & Komodakis, N. (2018). GraphVAE: Towards Generation of Small Graphs Using Variational Autoencoders. *arXiv preprint arXiv:1802.03480*.